We found an incidence of 77% of autoantibodies in patients with NHL at the time of diagnosis and before receiving their pharmacological cycle, which is higher than what was previously reported in the literature, which reported a prevalence ranging from 4% [16] of ANA antibodies to 41% [22] in other studies. This evidence concerns the gene BTG3 and non-Hodgkin lymphoma.